Arrowhead Pharmaceuticals, Inc.
A developer of RNA-interference medicines that silence disease-causing genes, Arrowhead's first FDA-approved drug, REDEMPLO, treats a rare condition called familial chylomicronemia syndrome by lowering triglycerides. The company began in 1989 as Arrowhead Research Corporation, a tech incubator that commercialized university patents, before pivoting to gene-silencing medicines after buying Roche's RNAi assets in 2011. Its name was chosen to symbolize a focused, forward-moving direction.
Granted 231.7K · Sold 360.2K
Granted 75.0K · Sold 49.5K
Granted 75.0K · Sold 110.2K
Granted 75.0K · Sold 13.1K
Granted 7.8K · Sold 16.3K
Granted 7.8K · Sold 16.3K
Granted 7.8K · Sold 8.4K
Granted 7.8K · Sold 3.0K
Granted 7.8K
Granted 7.8K · Sold 10.0K
Granted 7.8K · Sold 10.0K
Granted 11.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Anzalone Christopher RichardChief Executive Officer, Director · 28 transactions | -3.1% | 3.80M | 231.7K | — | 360.2K |
| O'Brien PatrickCOO · 23 transactions | -10.3% | 472.8K | 75.0K | — | 49.5K |
| Hamilton James CChief Medical Officer · 13 transactions | -13.4% | 227.0K | 75.0K | — | 110.2K |
| Apel Daniel JosephChief Financial Officer · 4 transactions | +70.7% | 172.8K | 75.0K | — | 13.1K |
| Perry Michael SDirector · 2 transactions | -6.4% | 123.1K | 7.8K | — | 16.3K |
| Ferrari MauroDirector · 3 transactions | -10.9% | 69.1K | 7.8K | — | 16.3K |
| Waddill William D.Director · 4 transactions | -1% | 56.6K | 7.8K | — | 8.4K |
| Lu HongboDirector · 2 transactions | +10.3% | 52.0K | 7.8K | — | 3.0K |
| Ingram Douglas SDirector · 1 transaction | — | 46.2K | 7.8K | — | — |
| Vakiener VictoriaDirector · 4 transactions | -0.7% | 37.7K | 7.8K | — | 10.0K |
| Olukotun Adeoye YDirector · 4 transactions | -6.1% | 33.6K | 7.8K | — | 10.0K |
| Cohen Matthew GregoryDirector · 1 transaction | — | 0 | 11.9K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -596.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.